Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Research ArticleClinical Investigations

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy

Richard P. Baum, Harshad R. Kulkarni, Christiane Schuchardt, Aviral Singh, Martina Wirtz, Stefan Wiessalla, Margret Schottelius, Dirk Mueller, Ingo Klette and Hans-Jürgen Wester
Journal of Nuclear Medicine July 2016, 57 (7) 1006-1013; DOI: https://doi.org/10.2967/jnumed.115.168443
Richard P. Baum
1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harshad R. Kulkarni
1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christiane Schuchardt
1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aviral Singh
1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martina Wirtz
2Pharmaceutical Radiochemistry, Faculties of Chemistry and Medicine, Technical University Munich, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Wiessalla
1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margret Schottelius
2Pharmaceutical Radiochemistry, Faculties of Chemistry and Medicine, Technical University Munich, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dirk Mueller
1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingo Klette
1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans-Jürgen Wester
2Pharmaceutical Radiochemistry, Faculties of Chemistry and Medicine, Technical University Munich, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 57 no. 7 1006-1013
DOI 
https://doi.org/10.2967/jnumed.115.168443
PubMed 
26795286

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication October 17, 2015
  • Accepted for publication December 15, 2015
  • Published online July 1, 2016.

Article Versions

  • previous version (January 21, 2016 - 05:36).
  • previous version (June 9, 2016 - 10:28).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author Information

  1. Richard P. Baum*,1,
  2. Harshad R. Kulkarni*,1,
  3. Christiane Schuchardt1,
  4. Aviral Singh1,
  5. Martina Wirtz2,
  6. Stefan Wiessalla1,
  7. Margret Schottelius2,
  8. Dirk Mueller1,
  9. Ingo Klette1 and
  10. Hans-Jürgen Wester2
  1. 1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; and
  2. 2Pharmaceutical Radiochemistry, Faculties of Chemistry and Medicine, Technical University Munich, Munich, Germany
  1. For correspondence or reprints contact: Richard P. Baum, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Robert-Koch-Allee 9, 99437 Bad Berka, Germany. E-mail: richard.baum{at}zentralklinik.de
View Full Text

Statistics from Altmetric.com

Cited By...

  • 338 Citations
  • 356 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
    Michael S Hofman, John Violet, Rodney J Hicks, Justin Ferdinandus, Sue Ping Thang, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Declan G Murphy, Peter Eu, Price Jackson, Mark Scalzo, Scott G Williams, Shahneen Sandhu
    The Lancet Oncology 2018 19 6
  • 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
    Wolfgang P. Fendler, Matthias Eiber, Mohsen Beheshti, Jamshed Bomanji, Francesco Ceci, Steven Cho, Frederik Giesel, Uwe Haberkorn, Thomas A. Hope, Klaus Kopka, Bernd J. Krause, Felix M. Mottaghy, Heiko Schöder, John Sunderland, Simon Wan, Hans-Jürgen Wester, Stefano Fanti, Ken Herrmann
    European Journal of Nuclear Medicine and Molecular Imaging 2017 44 6
  • Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
    Clemens Kratochwil, Frank Bruchertseifer, Hendrik Rathke, Markus Hohenfellner, Frederik L. Giesel, Uwe Haberkorn, Alfred Morgenstern
    Journal of Nuclear Medicine 2018 59 5
  • Radioactive Main Group and Rare Earth Metals for Imaging and Therapy
    Thomas I. Kostelnik, Chris Orvig
    Chemical Reviews 2019 119 2
  • Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
    John Violet, Price Jackson, Justin Ferdinandus, Shahneen Sandhu, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Sue Ping Thang, Peter Eu, Mark Scalzo, Declan Murphy, Scott Williams, Rodney J. Hicks, Michael S. Hofman
    Journal of Nuclear Medicine 2019 60 4
  • EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
    Clemens Kratochwil, Wolfgang Peter Fendler, Matthias Eiber, Richard Baum, Murat Fani Bozkurt, Johannes Czernin, Roberto C. Delgado Bolton, Samer Ezziddin, Flavio Forrer, Rodney J. Hicks, Thomas A. Hope, Levant Kabasakal, Mark Konijnenberg, Klaus Kopka, Michael Lassmann, Felix M. Mottaghy, Wim Oyen, Kambiz Rahbar, Heiko Schöder, Irene Virgolini, Hans-Jürgen Wester, Lisa Bodei, Stefano Fanti, Uwe Haberkorn, Ken Herrmann
    European Journal of Nuclear Medicine and Molecular Imaging 2019 46 12
  • Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging
    Sara Sheikhbahaei, Ali Afshar-Oromieh, Matthias Eiber, Lilja B. Solnes, Mehrbod S. Javadi, Ashley E. Ross, Kenneth J. Pienta, Mohamad E. Allaf, Uwe Haberkorn, Martin G. Pomper, Michael A. Gorin, Steven P. Rowe
    European Journal of Nuclear Medicine and Molecular Imaging 2017 44 12
  • Lutetium177PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
    Louise Emmett, Kathy Willowson, John Violet, Jane Shin, Ashley Blanksby, Jonathan Lee
    Journal of Medical Radiation Sciences 2017 64 1
  • Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer
    Matthias M. Heck, Robert Tauber, Sebastian Schwaiger, Margitta Retz, Calogero D’Alessandria, Tobias Maurer, Andrei Gafita, Hans-Jürgen Wester, Jürgen E. Gschwend, Wolfgang A. Weber, Markus Schwaiger, Karina Knorr, Matthias Eiber
    European Urology 2019 75 6
  • The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer
    Ali Afshar-Oromieh, John W. Babich, Clemens Kratochwil, Frederik L. Giesel, Michael Eisenhut, Klaus Kopka, Uwe Haberkorn
    Journal of Nuclear Medicine 2016 57 Supplement 3

Article usage

Article usage: January 2016 to August 2023

AbstractFullPdf
Jan 20165420152
Feb 20166090225
Mar 20164870165
Apr 20163700131
May 20164770125
Jun 20167040192
Jul 2016227392349
Aug 201683858181
Sep 201666265192
Oct 201655729168
Nov 201642155217
Dec 201630922148
Jan 2017415149214
Feb 2017473229257
Mar 2017629322261
Apr 2017403302188
May 2017373263246
Jun 2017231186150
Jul 201723897186
Aug 201727187158
Sep 201728884137
Oct 2017390168230
Nov 2017313120206
Dec 2017348119191
Jan 2018300138179
Feb 2018321118164
Mar 2018248100180
Apr 201822387157
May 2018232103151
Jun 20181829495
Jul 2018797880
Aug 20188317763
Sep 2018167532152
Oct 2018207459122
Nov 2018227477151
Dec 2018204525116
Jan 2019219678121
Feb 2019208682156
Mar 2019263703189
Apr 2019177144160
May 201918596139
Jun 201911255105
Jul 201924963107
Aug 201911751116
Sep 201915749103
Oct 201919750134
Nov 201914784153
Dec 20191106084
Jan 202015063119
Feb 202015258149
Mar 20201217192
Apr 20209864107
May 202013061107
Jun 202011070119
Jul 20201073285
Aug 20201246490
Sep 2020896283
Oct 20201348978
Nov 202016591120
Dec 2020127105111
Jan 202191133145
Feb 202110412887
Mar 2021128200168
Apr 2021110184145
May 2021118380108
Jun 2021123418167
Jul 202199369107
Aug 202187354108
Sep 202181226130
Oct 202167137135
Nov 202193146122
Dec 202168120107
Jan 202280137120
Feb 202265132115
Mar 2022113193160
Apr 202278223134
May 202277263143
Jun 202279239108
Jul 202283276144
Aug 202289271160
Sep 202279267121
Oct 20227419787
Nov 202277247150
Dec 20224417689
Jan 20236921195
Feb 202353216107
Mar 202389240102
Apr 202360171101
May 202385177122
Jun 202362217103
Jul 20234318284
Aug 202354275105
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 57 (7)
Journal of Nuclear Medicine
Vol. 57, Issue 7
July 1, 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
Richard P. Baum, Harshad R. Kulkarni, Christiane Schuchardt, Aviral Singh, Martina Wirtz, Stefan Wiessalla, Margret Schottelius, Dirk Mueller, Ingo Klette, Hans-Jürgen Wester
Journal of Nuclear Medicine Jul 2016, 57 (7) 1006-1013; DOI: 10.2967/jnumed.115.168443

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
Richard P. Baum, Harshad R. Kulkarni, Christiane Schuchardt, Aviral Singh, Martina Wirtz, Stefan Wiessalla, Margret Schottelius, Dirk Mueller, Ingo Klette, Hans-Jürgen Wester
Journal of Nuclear Medicine Jul 2016, 57 (7) 1006-1013; DOI: 10.2967/jnumed.115.168443
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • Perspective on 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer
  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study
  • Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T
  • Feasibility of Single-Time-Point Dosimetry for Radiopharmaceutical Therapies
  • First Clinical Results for PSMA-Targeted {alpha}-Therapy Using 225Ac-PSMA-I&T in Advanced-mCRPC Patients
  • Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies
  • 177Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer
  • JHU-2545 Selectively Shields Salivary Glands and Kidneys during PSMA-Targeted Radiotherapy
  • Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
  • Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine
  • 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney
  • Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics
  • Effect of External Cooling on 177Lu-PSMA Uptake by the Parotid Glands
  • Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy
  • A Single Dose of 225Ac-RPS-074 Induces a Complete Tumor Response in an LNCaP Xenograft Model
  • Preserving Preclinical PET Quality During Intratherapeutic Imaging in Radionuclide Therapy with Rose Metal Shielding Reducing Photon Flux
  • Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window
  • Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
  • Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer
  • Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies
  • A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies
  • Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms
  • The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for 177Lu-Labeled PSMA Peptides
  • Targeted {alpha}-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
  • Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer
  • PSMA Ligands for PET Imaging of Prostate Cancer
  • Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer
  • Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
  • Acceleration of PSMA-Targeted Theranostics to the Clinic: Can Common Sense Prevail?
  • 177Lu-PSMA Radioligand Therapy for Prostate Cancer
  • 68Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with 223Ra: Proof of Concept
  • Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617
  • 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience
  • From NETTER to PETTER: PSMA-Targeted Radioligand Therapy
  • Targeted {alpha}-Based Treatment of Metastatic Castration-Resistant Prostate Cancer: Revolutionizing Systemic Radiotherapy?
  • Nuclear Medicine in Cancer Theranostics: Beyond the Target
  • The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer
  • PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013
  • Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer
  • Perspective on 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer
  • Google Scholar

More in this TOC Section

  • Prognostic Role of 68Ga-PSMA11 PET–Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy
  • Radioimmunoscintigraphy and Pretreatment Dosimetry of 131I-Omburtamab for Planning Treatment of Leptomeningeal Disease
  • Efficacy and Safety of 124I-MIBG Dosimetry-Guided High-Activity 131I-MIBG Therapy of Advanced Pheochromocytoma or Neuroblastoma
Show more Clinical Investigations

Similar Articles

Keywords

  • PSMA
  • radioligand therapy
  • theranostics
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire